Clinical Trials

Lymphatic malformation

Displaying 2 studies

  • RLY-2608-201-Ph2 Study Of RLY-2608 In PROS And PIK3CA Driven Malformations Rochester, MN

    The purpose of this study is to compare the efficacy and safety of RLY-2608 versus placebo in adult, adolescent, and pediatric participants with PROS and malformations driven by PIK3CA mutations, which is preceded by a dose selection and basket design with exploratory single-arm cohorts for various subpopulations of participants.

  • A Study to Evaluate Topical VT30 to Treat Patients with Venous/Lymphatic Malformations Associated with PIK3CA or TEK Gene Mutations Rochester, MN

    The primary purpose of this two-part study is to evaluate the safety and tolerability of VT30.  

    Part 1 is a 4-week treatment, open-label, 4-sequence, escalating repeat-application cohort study, with intra-subject and inter-cohort dose escalation.

    Part 2 is a 12-week treatment, randomized, placebo-controlled, double-blind, safety and exploratory effectiveness study. Part 2 will be initiated only after the successful completion of Part 1 with results that demonstrate the general safety and tolerability of topically applied VT30. 

.

Mayo Clinic Footer